{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-092654","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.581992+00:00","generated_at":"2026-05-15T19:53:24.311529+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tenaya enters cardiovascular gene target collaboration with Alnylam; up to $10M upfront, $1.13B milestones","bullets":["Tenaya and Alnylam collaborate to discover/validate up to 15 cardiovascular gene targets; 24-month research term.","Tenaya receives up to $10M upfront payment within 30 days, subject to reductions for targets not advanced.","Tenaya eligible for up to $1.13B in development, regulatory, and sales milestones for company-nominated targets.","Alnylam gets exclusive worldwide license; may unilaterally terminate for any reason. Tenaya restricted on certain targets.","Alnylam reimburses Tenaya for FTEs and out-of-pocket costs per research budget; each party covers own costs otherwise."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-092654","json":"https://secwatch.observer/filing/0001193125-26-092654.json","markdown":"https://secwatch.observer/filing/0001193125-26-092654.md","text":"https://secwatch.observer/filing/0001193125-26-092654.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000119312526092654/0001193125-26-092654-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000119312526092654/tnya-20260304.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:53:24.311529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e9f8b72fa86290bd65b614de6657d6a9716951d8","claim":"Tenaya Therapeutics, Inc. entered into Collaboration Agreement with Alnylam Pharmaceuticals, Inc. valued at up to $10.0 million (effective 2026-03-04).","evidence_excerpt":"On March 4, 2026, Tenaya Therapeutics, Inc. (the “Company”) entered into a collaboration agreement (the “Collaboration Agreement”) with Alnylam Pharmaceuticals, Inc. (“Alnylam”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858848/000119312526092654/0001193125-26-092654-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Alnylam Pharmaceuticals, Inc."},{"label":"Value","value":"up to $10.0 million"},{"label":"Effective","value":"2026-03-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}